Article info

other Versions

Download PDFPDF
PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer

Authors

  1. Correspondence to Dr Anneke Westermann, Department of Medical Oncology, Academic Medical Centre, Amsterdam 1105, The Netherlands; a.m.westermann{at}amsterdamumc.nl
View Full Text

Citation

Westermann A, Ottevanger P, Reyners A, et al
PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer

Publication history

  • Received August 1, 2023
  • Accepted December 5, 2023
  • First published January 6, 2024.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.